ArticleACS omega2025
Amphibian-Derived Cathelicidin-DM and Cathelicidin-BG: Recombinant Overexpression in Escherichia coli and Comparison of Their Structures and Antimicrobial Activities.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cathelicidin-DM and cathelicidin-BG are homologous and are expected to be similar in structure and biological activity. However, while all structural prediction tools tested showed cathelicidin-BG to be helical, there were mixed results for cathelicidin-DM, with most predicting it to contain three antiparallel β-sheets and no helices. Also, separate researchers, in nonidentical conditions, reported cathelicidin-BG to possess antimicrobial activity against only Gram-positive bacteria, unlike cathelicidin-DM, which affected both Gram-positive and Gram-negative bacteria, suggesting more dissimilarities between the peptides. We therefore decided to experimentally verify and compare the structures and activities of the peptides. Until now, there is no experimentally determined structural information on either peptide, and no cheap, efficient procedure has been reported for their mass production. We hereby report a recombinant method for cathelicidin-DM and cathelicidin-BG overexpression and purification, which yielded 1.19 and 1.92 mg of pure peptides, respectively, per 0.5 L of Luria-Bertani culture. At all oxidation states, both peptides adopted a random coil structure in sodium phosphate buffer (SPB) at pH 7.4, but switched to a helical conformation in membrane mimetics. In SPB, both native peptides demonstrated strong activity against both Gram-positive and Gram-negative bacteria, with ≤5 μM of each peptide killing all cells of the tested bacterial strains, through membrane disruption as one of the possible mechanisms. We therefore conclude that, under the conditions studied, both cathelicidins have comparable structures and antimicrobial activities as their sequence homology suggested; and we recommend the use of laboratory experimentations for validation of structural prediction results.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.